Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

Hanley, Gillian E.; Kaur, Paramdeep; Berchuck, Andrew; Chase, Anne; Grout, Bronwyn; Deurloo, Cindy McKinnon; Pike, Malcolm C.; Richardson, Jean L.; Terry, Kathryn L.; Webb, Penelope M.; Pearce, Celeste Leigh

doi:10.1016/j.ygyno.2021.05.021

Cited by 10 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Description of included studies. The initial search strategy retrieved 402 studies, and after careful review, 16 were ultimately included (12,(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34). These 16 studies were published from 2008-2022 and contained a total of 37,660 patients with OC, of whom 11,296 were statin users.…”

Section: Resultsmentioning

confidence: 99%

“…Of the included studies, 4 were conducted on Asian participants (12,27,31,32) and 12 on non-Asian participants (20)(21)(22)(23)(24)(25)(26)(28)(29)(30)33,34). In total, 5 studies were from the United States of America (20,22,23,28,34), 2 were conducted each in Australia (25,29), Denmark (24,33) and Israel (12,27), and 1 study was conducted each in Korea (31), China (32), Canada (30), Finland (21) and Belgium (26). All studies directly reported HRs and 95% CIs, and 4 studies enrolled <200 patients with OC (12,20,27,32).…”

Section: Resultsmentioning

confidence: 99%

“…All studies directly reported HRs and 95% CIs, and 4 studies enrolled <200 patients with OC (12,20,27,32). Among the included studies, 13 were cohort studies (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)33,34) with a total sample size of 37,324, while 3 were case-control studies (12,20,32) with a total sample size of 336. Overall, 3 prospective studies (25,33,34) and 13 retrospective studies (12,(20)(21)(22)(23)(24)(26)(27)(28)(29)(30)(31)(32) were included.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta‑analysis

et al. 2022

View full text Add to dashboard Cite

Statins are lipid-lowering agents that have also been found to have anticancer effects. The relationship between statin use and clinical outcomes in ovarian cancer (OC) remains controversial, as previous assessments of the relationship between statin use and OC prognosis have yielded inconsistent results. Therefore, a comprehensive meta-analysis was performed in the present study to investigate this association. Studies were systematically retrieved by searching the PubMed, Embase and Cochrane Library databases, and consulting reference lists of the related studies. The search timeframe was from database creation to September 1, 2022. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the association. In the present meta-analysis, 16 studies with 37,660 patients with OC were included, of which 11,296 patients had been prescribed statins. The results showed that statin use markedly improved the overall survival time (OS; HR, 0.79; 95% CI, 0.73-0.85; P<0.00001) and OC-specific survival time (HR, 0.84; 95% CI, 0.80-0.89; P<0.00001), especially the OS time in patients with serous OC (HR, 0.81; 95% CI, 0.74-0.89; P<0.0001) and endometrioid OC (HR, 0.80; 95% CI, 0.66-0.98; P=0.03). In addition, survival rate was higher in patients who used statins after OC diagnosis (HR, 0.79; 95% CI, 0.73-0.85; P<0.00001). However, there was no statistically significant association between statin use and the prognosis of mucinous and clear cell OC. The results suggested that statin use markedly improved the OS in patients with OC, including in those with serous and endometrioid OC. Statins were also found to improve the prognosis of patients of both Asian and non-Asian ethnicities. In addition, both lipophilic and hydrophilic statins improved the survival in patients with OC, especially in patients using statins after OC diagnosis. However, the effect may vary depending on the statin type, duration of use and cancer type, and more well-designed studies are needed to further evaluate this.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta‑analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is the second most common malignances after breast cancer in females, with a global incidence of roughly 200 000 cases per year . Unfortunately, most patients are already in the middle and late stages upon primary diagnosis, consequently missing the optimal opportunity for efficient treatment . As a result, its early diagnosis and treatment prove feasibility to prevent such cancer.…”

Section: Introductionmentioning

confidence: 99%

“…1 Unfortunately, most patients are already in the middle and late stages upon primary diagnosis, consequently missing the optimal opportunity for efficient treatment. 2 As a result, its early diagnosis and treatment prove feasibility to prevent such cancer. Clinical studies reveal that its occurrence and development have tight correlation with tumor biomarkers such as human epididymis protein 4 (HE4) in human blood.…”

Section: ■ Introductionmentioning

confidence: 99%

Dual-Mode Photoelectrochemical and Electrochemical Immunosensors for Human Epididymis Protein 4 Based on SPR-Promoted Au Nanoparticle/CdS Nanosheet Heterostructures

Wei

Wang

Zheng

et al. 2022

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

As a promising biomarker, human epididymis protein 4 (HE4) shows wide applications for early diagnosis and therapy of ovarian cancer. Herein, heterostructured Au nanoparticles/CdS nanosheet (Au NPs/CdS NS) were initially constructed by two-step electrodeposition and used to build photoelectrochemical (PEC) and electrochemical (EC) dual-mode immunosensors for the detection of HE4. As one of appealing properties, surface Plasmon resonance (SPR) effects of Au NPs endowed the Au NPs/ CdS NS heterostructures with highly enhanced PEC and EC signals upon light irradiation, which were gradually weakened by elevating the HE4 concentrations. Under the optimal conditions, the dual-mode sensor displayed wider linear ranges of 0.01−100 and 0.01−200 ng mL −1 for PEC and EC modes, respectively. The detection limits were 1.084 and 1.188 pg mL −1 for PEC and EC detections, respectively. This sensing platform holds great potential for the analysis of other biomarkers in the clinical field.

show abstract

Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

Kaur,

Berchuck,

Chase

et al. 2024

Neoplasia

View full text Add to dashboard Cite

Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

Cited by 10 publications

References 24 publications

Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta‑analysis

Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta‑analysis

Dual-Mode Photoelectrochemical and Electrochemical Immunosensors for Human Epididymis Protein 4 Based on SPR-Promoted Au Nanoparticle/CdS Nanosheet Heterostructures

Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada

Contact Info

Product

Resources

About